Page 4 - Diffuse News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Diffuse. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Diffuse Today - Breaking & Trending Today

ADC Therapeutics SA: ADC Therapeutics and Sobi Announce ZYNLONTA (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

Approval decision expected in 4Q 2022 ADC Therapeutics SA (NYSE: ADCT) and Swedish Orphan Biovitrum AB (Sobi) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European ....

United Kingdom , United States , New Jersey , City Of , Amanda Loshbaugh , Lausanne Biop , Mary Ann Ondish , Anders Ullman , John Radford , Eugenia Litz , Company On Twitter , Mitsubishi Tanabe Pharma Corporation , European Commission , University Of Manchester , Drug Administration , Foundation Trust In Manchester , Exchange Commission , European Medicines Agency , Overland Pharmaceuticals , Committee For Medicinal Products Human Use , Head Of Research Development , Swedish Orphan Biovitrum , Medicinal Products , Human Use , Ameet Mallik , Chief Executive Officer ,

Loncastuximab tesirine receives positive CHMP opinion for the treatment of relapsed or refractory diffuse large B-cell lymphoma: Swedish Orphan Biovitrum AB

STOCKHOLM, Sept. 16, 2022 /PRNewswire/ Sobi and ADC Therapeutics SA today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted ....

United Kingdom , United States , New Jersey , City Of , Lausanne Biop , Anders Ullman , John Radford , Thomas Kudsk Larsen , Prnewswire Sobi , Company On Twitter , European Commission , University Of Manchester , Drug Administration , Sobi Investor Relations Team , Foundation Trust In Manchester , European Medicines Agency , Committee For Medicinal Products Human Use , Head Of Research Development , Medicinal Products , Human Use , Chief Medical Officer , Ameet Mallik , Chief Executive Officer , Medical Oncology , San Francisco Bay Area , Cancer Research United Kingdom ,

F. Hoffmann-La Roche Ltd: FDA accepts supplemental Biologics License Application for Roche's Polivy combination for people with previously untreated diffuse large B-cell lymphoma

First new treatment regimen in more than 20 years to significantly improve outcomes in people with this fast-growing type of lymphoma Application is based on pivotal data from the phase III POLARIX study ....

United States , Gazyvaro Gazyva , Mabthera Rituxan , Sabine Borngr , Gerard Tobin , Bruno Eschli , Venclexta Venclyxto , Birgit Masjost , Sileia Urech , Loren Kalm , Karsten Kleine , Nathalie Altermatt , Lymphoma Study Association , Roche Group , Roche Group Media Relations , Lymphoma Academic Research Organisation , Lugano Response Criteria , Dow Jones Sustainability Indices , Chugai Pharmaceutical ,

Nordic Nanovector Announces that the data from the LYMRIT 37-05 Phase 1 Trial of Betalutin in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) will be presented at EHA 2022 Meeting

OSLO, Norway, June 10, 2022 /PRNewswire/ Nordic Nanovector ASA (OSE: NANOV) announces an update from the LYMRIT 37-05 Phase 1 trial investigating Betalutin (177Lu lilotomab satetraxetan) ....

Gomez Codina , Erik Skullerud , Malene Brondberg , Frazer Hall Medi , European Hematology Association , Nordic Nanovector , Abstract Code , Stem Cell Transplantation , South Asian , Disease Landscape , Frazer Hall , Securities Trading ,

EU Approves Roche's Polivy Combination For Previously Untreated Diffuse Large B-cell Lymphoma

SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY) said that the European Commission has granted approval of Polivy or polatuzumab vedotin in combination with MabThera or rituximab plus cyclophosphamide ....

European Union , European Commission ,